LDL-cholesterol trajectories and statin treatment in Finnish type 2 diabetes patients: a growth mixture model.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
19 11 2021
19 11 2021
Historique:
received:
04
05
2021
accepted:
08
11
2021
entrez:
20
11
2021
pubmed:
21
11
2021
medline:
8
3
2022
Statut:
epublish
Résumé
We aimed to identify distinct longitudinal trends of LDL-cholesterol (LDL-C) levels and investigate these trajectories' association with statin treatment. This retrospective cohort study used electronic health records from 8592 type 2 diabetes patients in North Karelia, Finland, comprising all primary and specialised care visits 2011‒2017. We compared LDL-C trajectory groups assessing LDL-C treatment target achievement and changes in statin treatment intensity. Using a growth mixture model, we identified four LDL-C trajectory groups. The majority (85.9%) had "moderate-stable" LDL-C levels around 2.3 mmol/L. The second-largest group (7.7%) consisted of predominantly untreated patients with alarmingly "high-stable" LDL-C levels around 3.9 mmol/L. The "decreasing" group (3.8%) was characterised by large improvements in initially very high LDL-C levels, along with the highest statin treatment intensification rates, while among patients with "increasing" LDL-C (2.5%), statin treatment declined drastically. In all the trajectory groups, women had significantly higher average LDL-C levels and received less frequent any statin treatment and high-intensity treatment than men. Overall, 41.9% of patients had no statin prescribed at the end of follow-up. Efforts to control LDL-C should be increased-especially in patients with continuously elevated levels-by initiating and intensifying statin treatment earlier and re-initiating the treatment after discontinuation if possible.
Identifiants
pubmed: 34799657
doi: 10.1038/s41598-021-02077-6
pii: 10.1038/s41598-021-02077-6
pmc: PMC8604948
doi:
Substances chimiques
Cholesterol, LDL
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
22603Subventions
Organisme : Strategic Research Council of the Academy of Finland
ID : 312703
Informations de copyright
© 2021. The Author(s).
Références
Ference, B. A. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 38, 2459–2472 (2017).
pubmed: 28444290
pmcid: 5837225
doi: 10.1093/eurheartj/ehx144
Einarson, T. R., Acs, A., Ludwig, C. & Panton, U. H. Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc. Diabetol. 17, 83 (2018).
pubmed: 29884191
pmcid: 5994068
doi: 10.1186/s12933-018-0728-6
Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 379, 633–644 (2018).
pubmed: 30110583
doi: 10.1056/NEJMoa1800256
International Diabetes Federation. Recommendations for Managing Type 2 Diabetes in Primary Care (2017).
American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes-2019. Diabetes Care 42, 103–123 (2019).
doi: 10.2337/dc19-S010
Mach, F. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111–188 (2020).
pubmed: 31504418
doi: 10.1093/eurheartj/ehz455
Current Care Guidelines. Dyslipidemia. Accessed 3 Dec 2019. https://www.kaypahoito.fi/hoi50025 (2019).
Stone, M. A. et al. Quality of care of people with type 2 diabetes in eight European countries: Findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care 36, 2628–2638 (2013).
pubmed: 23628621
pmcid: 3747883
doi: 10.2337/dc12-1759
Steen, D. L., Khan, I., Ansell, D., Sanchez, R. J. & Ray, K. K. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: Comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. BMJ Open 7, e013255 (2017).
pubmed: 28213597
pmcid: 5318572
doi: 10.1136/bmjopen-2016-013255
Svensson, A.-M. et al. Nationella Diabetesregistret, årsrapport 2020 (2020).
Morieri, M. L., Avogaro, A. & Fadini, G. P. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: Unmet needs in a large population of outpatients at specialist clinics. Cardiovasc. Diabetol. 19, 190 (2020).
pubmed: 33172454
pmcid: 7653689
doi: 10.1186/s12933-020-01164-8
Ruokoniemi, P., Helin-Salmivaara, A., Klaukka, T., Neuvonen, P. J. & Huupponen, R. Shift of statin use towards the elderly in 1995–2005: A nation-wide register study in Finland. Br. J. Clin. Pharmacol. 66, 405–410 (2008).
pubmed: 18782143
pmcid: 2526244
doi: 10.1111/j.1365-2125.2008.03258.x
Lonka, V., Taipale, H., Saastamoinen, L. K., Kettunen, R. & Hartikainen, S. Kaikkein iäkkäimmät käyttävät statiineja yhä yleisemmin [The oldest are increasingly using statins]. Veera, Lonka; Heidi, Taipale; Leena K. Saastamoinen Raimo Kettunen Sirpa Hartikainen. Finn. Med. J. 72, 2363–2367 (2017).
Lamidi, M.-L. et al. Trends in the process and outcome indicators of type 2 diabetes care: A cohort study from Eastern Finland, 2012–2017. BMC Fam. Pract. 21, 253 (2020).
pubmed: 33276719
pmcid: 7718663
doi: 10.1186/s12875-020-01324-5
Duncan, M. S., Vasan, R. S. & Xanthakis, V. Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all-cause mortality: Observations from the Framingham Study over 35 years. J. Am. Heart Assoc. 8, e011433 (2019).
pubmed: 31137992
pmcid: 6585376
doi: 10.1161/JAHA.118.011433
Pencina, K. M. et al. Trajectories of non-HDL cholesterol across midlife: Implications for cardiovascular prevention. J. Am. Coll. Cardiol. 74, 70–79 (2019).
pubmed: 31272554
pmcid: 7346311
doi: 10.1016/j.jacc.2019.04.047
Tsai, C.-W. et al. Longitudinal lipid trends and adverse outcomes in patients with CKD: A 13-year observational cohort study. J. Lipid Res. 60, 648–660 (2019).
pubmed: 30642880
pmcid: 6399497
doi: 10.1194/jlr.P084590
WHO. About the ATC/DDD system. Accessed 19 Nov 2020. https://www.whocc.no/atc_ddd_index/ (2020).
WHO. ICD-10: International Statistical Classification of Diseases and Related Health Problems 10th edn. (World Health Organization, 2004).
Contact Point for Cross-Border Healthcare. Healthcare system in Finland. Accessed 10 Aug 2021. https://www.eu-healthcare.fi/healthcare-in-finland/healthcare-system-in-finland/ (2021).
Ministry of Social Affairs and Health (STM). Terveydenhuollon maksut [Health care fees]. Accessed 10 Aug 2021. https://stm.fi/terveydenhuollon-maksut (2021).
Finnish Social Insurance Institution. Rates of reimbursement. Available at B. Accessed 10 Aug 2021. https://www.kela.fi/web/en/reimbursements-for-medicine-expences-amount?inheritRedirect=true (2015).
Current Care Guidelines. Type 2 diabetes. Accessed 5 Sept 2020. https://www.kaypahoito.fi/hoi50056 (2020).
Nicolucci, A., Greenfield, S. & Mattke, S. Selecting indicators for the quality of diabetes care at the health systems level in OECD countries. Int. J. Qual. Health Care J. Int. Soc. Qual. Health Care 18(Suppl 1), 26–30 (2006).
doi: 10.1093/intqhc/mzl023
Stone, N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S1-45 (2014).
pubmed: 24222016
doi: 10.1161/01.cir.0000437738.63853.7a
Nagin, D. S. & Odgers, C. L. Group-based trajectory modeling in clinical research. Annu. Rev. Clin. Psychol. 6, 109–138 (2010).
pubmed: 20192788
doi: 10.1146/annurev.clinpsy.121208.131413
Nylund-Gibson, K. & Choi, A. Y. Ten frequently asked questions about latent class analysis. Transl. Issues Psychol. Sci. 4, 440–461 (2018).
doi: 10.1037/tps0000176
Muthén, L. K. & Muthén, B. O. Mplus User’s Guide (Muthén & Muthén, 2012).
R Core Team. R: A Language and Environment for Statistical Computing. https://www.R-project.org/ . (R Foundation for Statistical Computing, 2020).
Vehko, T. et al. Monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: A nationwide register-based study. BMJ Open 3, e003414 (2013).
pubmed: 24189078
pmcid: 3822306
doi: 10.1136/bmjopen-2013-003414
März, W. et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis 268, 99–107 (2018).
pubmed: 29197254
doi: 10.1016/j.atherosclerosis.2017.11.020
Silvennoinen, R., Turunen, J. H., Kovanen, P. T., Syvänne, M. & Tikkanen, M. J. Attitudes and actions: A survey to assess statin use among Finnish patients with increased risk for cardiovascular events. J. Clin. Lipidol. 11, 485–494 (2017).
pubmed: 28502506
doi: 10.1016/j.jacl.2017.02.013
Helin-Salmivaara, A., Lavikainen, P., Ruokoniemi, P., Korhonen, M. & Huupponen, R. Persistence with statin therapy in diabetic and non-diabetic persons: A nation-wide register study in 1995–2005 in Finland. Diabetes Res. Clin. Pract. 84, e9–e11 (2009).
pubmed: 19167127
doi: 10.1016/j.diabres.2008.12.015
Graversen, L., Christensen, B., Borch-Johnsen, K., Lauritzen, T. & Sandbaek, A. General practitioners’ adherence to guidelines on management of dyslipidaemia: ADDITION-Denmark. Scand. J. Prim. Health Care 28, 47–54 (2010).
pubmed: 19929180
pmcid: 3440615
doi: 10.3109/02813430903335216
Bradley, C. K. et al. Patient-reported reasons for declining or discontinuing statin therapy: Insights from the PALM registry. J. Am. Heart Assoc. 8, e011765 (2019).
pubmed: 30913959
pmcid: 6509731
doi: 10.1161/JAHA.118.011765
Mampuya, W. M. et al. Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience. Am. Heart J. 166, 597–603 (2013).
pubmed: 24016512
pmcid: 4038261
doi: 10.1016/j.ahj.2013.06.004
Hope, H. F. et al. Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS One 14, e0201196 (2019).
pubmed: 30653535
pmcid: 6336256
doi: 10.1371/journal.pone.0201196
Aarnio, E. J. et al. Register-based predictors of adherence among new statin users in Finland. J. Clin. Lipidol. 8, 117–125 (2014).
pubmed: 24528692
doi: 10.1016/j.jacl.2013.09.008
Lavikainen, P. et al. Statin adherence and risk of acute cardiovascular events among women: A cohort study accounting for time-dependent confounding affected by previous adherence. BMJ Open 6, e011306 (2016).
pubmed: 27259530
pmcid: 4893857
doi: 10.1136/bmjopen-2016-011306
Current Care Guidelines. Dyslipidemia. Accessed 2 Aug 2021. https://www.kaypahoito.fi/hoi50025 (2021).
Zhang, X. et al. Gender disparities in lipid goal attainment among type 2 diabetes outpatients with coronary heart disease: Results from the CCMR-3B Study. Sci. Rep. 7, 12648 (2017).
pubmed: 28978912
pmcid: 5627285
doi: 10.1038/s41598-017-13066-z
Rossi, M. C. et al. Sex disparities in the quality of diabetes care: Biological and cultural factors may play a different role for different outcomes: A cross-sectional observational study from the AMD Annals initiative. Diabetes Care 36(10), 3162–3168 (2013).
pubmed: 23835692
pmcid: 3781503
doi: 10.2337/dc13-0184
Franconi, F. et al. Gender differences in drug responses. Pharmacol. Res. 55(2), 81–95 (2007).
pubmed: 17129734
doi: 10.1016/j.phrs.2006.11.001
Khatiwada, S. et al. Thyroid dysfunction and associated risk factors among nepalese diabetes mellitus patients. Int. J. Endocrinol. 2015, 570198 (2015).
pubmed: 26435714
pmcid: 4576006
doi: 10.1155/2015/570198
Meng, Z. et al. Gender and age impacts on the association between thyroid function and metabolic syndrome in Chinese. Medicine (Baltimore) 94(50), e2193 (2015).
doi: 10.1097/MD.0000000000002193
Wouters, H. et al. Understanding statin non-adherence: Knowing which perceptions and experiences matter to different patients. PLoS one 11, e0146272 (2016).
pubmed: 26808151
pmcid: 4726652
doi: 10.1371/journal.pone.0146272
Newman, C. B. et al. Statin safety and associated adverse events: A scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 39, e38–e81 (2019).
pubmed: 30580575
doi: 10.1161/ATV.0000000000000073
Gupta, A. et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): A randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 389, 2473–2481 (2017).
pubmed: 28476288
doi: 10.1016/S0140-6736(17)31075-9
Matthews, A. et al. Impact of statin related media coverage on use of statins: Interrupted time series analysis with UK primary care data. BMJ (Clinical Research Ed.) 353, i3283 (2016).
Nielsen, S. F. & Nordestgaard, B. G. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: A nationwide prospective cohort study. Eur. Heart J. 37, 908–916 (2016).
pubmed: 26643266
doi: 10.1093/eurheartj/ehv641
Nelson, A. J., Puri, R. & Nissen, S. E. Statins in a distorted mirror of media. Curr. Atheroscler. Rep. 22, 37 (2020).
pubmed: 32557172
doi: 10.1007/s11883-020-00853-9
Chisnell, J., Marshall, T., Hyde, C., Zhelev, Z. & Fleming, L. E. A content analysis of the representation of statins in the British newsprint media. BMJ Open 7, e012613 (2017).
pubmed: 28827228
pmcid: 5724098
doi: 10.1136/bmjopen-2016-012613
Tanner, R. M. et al. Primary care physician perspectives on barriers to statin treatment. Cardiovasc. Drugs Ther. 31, 303–309 (2017).
pubmed: 28710589
pmcid: 6939993
doi: 10.1007/s10557-017-6738-x
Brito, J. P. & Montori, V. M. Reinitiation of statins after statin-associated musculoskeletal symptoms: A patient-centered approach. Circ. Cardiovasc. Qual. Outcomes 6, 243–247 (2013).
pubmed: 23481527
doi: 10.1161/CIRCOUTCOMES.111.000039
Abughosh, S. M. et al. Enhancing statin adherence using a motivational interviewing intervention and past adherence trajectories in patients with suboptimal adherence. J. Manag. Care Spec. Pharm. 25, 1053–1062 (2019).
pubmed: 31556824
Mikkola, I., Hagnäs, M., Hartsenko, J., Kaila, M. & Winell, K. A personalized care plan is positively associated with better clinical outcomes in the care of patients with type 2 diabetes: A cross-sectional real-life study. Can. J. Diabetes 44, 133–138 (2020).
pubmed: 31399365
doi: 10.1016/j.jcjd.2019.05.003
Finnish Social Insurance Institution. My Kanta Pages. Accessed 15 May 2021. https://www.kanta.fi/en/data-in-kanta (2020).
Wikström, K. et al. Electronic health records as valuable data sources in the health care quality improvement process. Health Serv. Res. Manag. Epidemiol. 6, 2333392819852879 (2019).
pubmed: 31211180
pmcid: 6545647